Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuvirtide + cabotegravir in virologically suppressed HIV patients (28-week efficacy, PK, and safety)
ChiCTR2400089435Phase 4Completed
- Sponsor
- Guangzhou Eighth People's Hospital
- Start
- Aug 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of albuvirtide and cabotegravir in human immunodeficiency virus infection (HIV), sponsored by Guangzhou Eighth People's Hospital. Primary endpoint: Viral suppression failure rate at week 28. Started Aug 2024; status: completed.
02
Drugs
albuvirtidecabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2400089435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089435.